Vimarsana
Biggest News Aggregation in the World

Page 13 - Rye Brook News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rye Brook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rye Brook Today - Breaking & Trending Today

Betsy Buttrill White, banker-turned-educator, dies at 73 - Westfair Communications - Vimarsana News

Betsy Buttrill White, banker-turned-educator, dies at 73 - Westfair Communications

Betsy Buttrill White, a prominent figure in banking, education and the nonprofit sector, passed away on Dec. 28 at her Rye Brook home at the age of 73.

Truck Explodes Causing Huge Fireball After Hitting Bridge in NY - Vimarsana News

Truck Explodes Causing Huge Fireball After Hitting Bridge in NY

A truck driver suffered serious burns after hitting a bridge in New York state. the impact caused a huge explosion, sending flames as high as 200 feet into the air.

Truck Explodes Causing Huge Fireball After Hitting Bridge in NY - Vimarsana News

Truck Explodes Causing Huge Fireball After Hitting Bridge in NY

A truck driver suffered serious burns after hitting a bridge in New York state. the impact caused a huge explosion, sending flames as high as 200 feet into the air.

Source: wpdh.com
Bona Fide Masks(R) Continues to Provide High Quality, Authentic Masks ... - Vimarsana News

Bona Fide Masks(R) Continues to Provide High Quality, Authentic Masks ...

Bona Fide Masks(R) Continues to Provide High Quality, Authentic Masks ...

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial - Vimarsana News

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-

Source: yahoo.com